ORG-24598
![]() | This article may be too technical for most readers to understand.(August 2024) |
![]() | |
Names | |
---|---|
IUPAC name 2-[methyl-[(3R)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]acetic acid | |
Identifiers | |
3D model (JSmol) | |
ChEMBL | |
ChemSpider | |
PubChem CID | |
| |
| |
Properties | |
C19H20F3NO3 | |
Molar mass | 367.368 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
ORG-24598 is a selective inhibitor of the type 1 glycine transporter.[1]
Potential uses
[edit]Alcohol use disorder
[edit]A test in rats has showed that combining varenicline, bupropion and an indirect glycine agonist (such as ORG-24598) could be beneficial for treatment of alcohol use disorder.[2]
Schizophrenia
[edit]Studies have shown that glycine re-uptake inhibitors selective for the type 1 transporter may be useful for the treatment of certain schizophrenia symptoms.[3][4]
References
[edit]- ^ "2-[methyl-[(3R)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]acetic acid". pubchem.ncbi.nlm.nih.gov. Retrieved 2024-08-17.
- ^ Olsson, Yasmin; Lidö, Helga; Ademar, Karin; Cadeddu, Davide; Ericson, Mia; Söderpalm, Bo (January 2024). "The GlyT1-inhibitor Org 24598 facilitates the alcohol deprivation abolishing and dopamine elevating effects of bupropion + varenicline in rats". Journal of Neural Transmission (Vienna, Austria: 1996). 131 (1): 95–106. doi:10.1007/s00702-023-02701-x. ISSN 1435-1463. PMC 10769923. PMID 37773223.
- ^ Chue, Pierre (2013). "Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1)". Current Pharmaceutical Design. 19 (7): 1311–1320. doi:10.2174/138161213804805766. ISSN 1873-4286. PMID 23194655.
- ^ Javitt, Daniel C. (July 2002). "Glycine modulators in schizophrenia". Current Opinion in Investigational Drugs (London, England: 2000). 3 (7): 1067–1072. ISSN 1472-4472. PMID 12186269.